I've been noticing something interesting about the current market setup heading into spring 2026. With the Fed potentially shifting its rate policy and earnings expectations looking solid, there's actually been a quiet opportunity brewing in the sub-$10 stock space that a lot of retail investors seem to be missing.

Now, most people immediately think of penny stocks when they hear "cheap stocks," and yeah, those can be pretty wild and unpredictable. But there's a sweet spot in that $5 to $10 range where you occasionally find some genuinely solid companies that haven't blown up in price yet. The key is being selective and knowing what to look for.

I've been screening for stocks trading under $10 that have improving earnings revisions, solid analyst coverage, and real trading volume. Basically, I'm hunting for companies where the fundamentals are actually getting better, not worse. It's a different approach than just chasing the cheapest ticker you can find.

One that caught my attention recently is Amicus Therapeutics (FOLD). It's a biotech play focused on rare disease treatments, and honestly, the numbers have been pretty compelling. They posted 17% revenue growth in their last quarter and actually hit GAAP profitability, which is a big deal for a biotech company. They're treating more patients than ever, especially with their Galafold and Pombiliti + Opfolda products gaining traction.

Here's where it gets interesting. Revenue is expected to keep climbing around 19% through next year, hitting roughly $745 million. But the earnings growth is where things get spicy - they're projecting 50% earnings expansion this year and then 87% growth next year, reaching $0.67 per share. That's a massive jump from where they were in 2024.

The stock itself has already moved over 60% in the last six months and is sitting near some key technical levels. With the average price target suggesting 61% upside from current levels around $9.90, and about 82% of analysts rating it as a Strong Buy, this feels like one of those $10 dollar stocks that could actually explode if execution stays on track. The combination of improving fundamentals, analyst enthusiasm, and technical setup is exactly what I look for when hunting for undervalued opportunities that still have real upside potential.

This is just one example, but it shows why being selective in the sub-$10 space can actually pay off if you do your homework. The market's full of noise, but if you filter for real earnings improvements and analyst support, you can find some genuine opportunities hiding in plain sight.